IP Library Granted Patent US 8,067,177
Granted Patent B2
US 8,067,177 · App. 12/725,922 · Granted Nov 29, 2011

Amplification methods

Assignee: Epoch Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,177
App. No.
12/725,922
Granted
Nov 29, 2011
Kind
B2
Abstract

Methods are provided for amplification and monitoring of oligonucleotide amplification in which a primer has an overlap with one or more bases of a detection probe.

Claims (19)

1. A method for detecting polynucleotide amplification of a target sequence, comprising:

(a) providing a mixture comprising a sample containing a target sequence, with one or more than one oligonucleotide primers complementary to regions of the target sequence, a polymerizing enzyme, nucleotide substrates, and an oligonucleotide probe comprising a 5′ end and a 3′ end and two or more labels, wherein the oligonucleotide probe is an oligonucleotide conjugate, wherein one of the labels is a fluorophore and one of the labels is a quencher, wherein the oligonucleotide conjugate comprises an oligonucleotide or a modified oligonucleotide, wherein the oligonucleotide or modified oligonucleotide sequence has an overlap of from 1 to 7 bases with at least one of said primer sequences and the oligonucleotide or modified oligonucleotide has a sequence complementary to a portion of the target sequence being amplified;

(b) incubating the mixture under conditions favorable for polymerization and amplification of the target sequence; and

(c) detecting the amplification of the target sequence.

2. The method of claim 1 , wherein the oligonucleotide conjugate comprises a modified oligonucleotide comprising at least one modified base.

3. The method of claim 2 , wherein said at least one modified base is a base attached to a peptide nucleic acid (PNA) or a base attached to a locked nucleic acid.

4. The method of claim 3 , wherein said modified base is a base attached to PNA.

5. The method of claim 3 , wherein said modified base is a base attached to a locked nucleic acid.

6. The method of claim 2 , wherein the modified base is selected from the group consisting of 6-amino-1H-pyrazolo[3,4 d]pyrimidin 4(5H)-one (PPG), 4-amino-1H -pyrazolo[3,4 d]pyrimidine (PPA) and 1H-pyrazolo[5,4 d]pyrimidin 4(5H)-6(7H)-dione (ppX).

7. The method of claim 2 , wherein the modified base is selected from the group consisting of 6-amino-3-prop-1-ynyl-5-hydropyrazolo[3,4-d]pyrimidine-4-one (PPPG), 6-amino-3-(3-hydroxyprop-1-ynyl)1-5-hydropyrazolo[3,4-d]pyrimidine-4-one (HOPPPG), 6-amino-3-(3-aminoprop-1-ynyl)-5-hydropyrazolo[3,4-d]pyrimidine--4-one (NH 2 PPPG), 4-amino-3-(prop-1-ynyl)pyrazolo[3,4-d]pyrimidine (PPPA), 4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidine (HOPPPA), 4-amino-3-(3-aminoprop-1-ynyl)pyrazolo[3,4-d]pyrimidine (NH 2 PPPA), 3-prop-1-ynylpyrazolo[3,4-d]pyrimidine-4,6-diamino ((NH 2 ) 2 PPPA), 2-(4,6-diaminopyrazolo[3,4-d]pyrimidin-3-yl)ethyn-1-ol, ((NH 2 ) 2 PPPAOH), 3-(2-aminoethynyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine, ((NH 2 ) 2 PPPANH 2 ), 5-prop-1-ynyl-1,3-dihydropyrimidine-2,4-dione (PU), 5-(3-hydroxyprop-1-ynyl)-1,3-dihydropyrimidine-2,4-dione (HOPU), 6-amino-5-prop-1-ynyl-3-dihydropyrimidine-2-one (PC), 6-amino-5-(3-hydroxyprop-1-yny)-1,3-dihydropyrimidine-2-one (HOPC), 6-amino-5-(3-aminoprop-1-yny)-1,3-dihydropyrimidine-2-one (NH 2 PC), 5-[4-amino-3-(3-methoxyprop-1-ynyl)pyrazol[3,4-d]pyrimidinyl]-2-(hydroxy-methyl)oxolan-3-ol (CH 3 OPPPA), 6-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-(3-methoxyprop-1-yny-1)-5-hydropyrazolo[3,4-d]pyrimidin-4-one (CH 3 OPPPG), 4,(4,6-Diamino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-but-3-yn-1-ol (Super A), 6-Amino-3-(4-hydroxy-but-1-ynyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one, 5-(4-hydroxy-but-1-ynyl)-1H-pyrimidine-2,4-dione (Super T), 3-iodo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH 2 ) 2 PPAI), 3-bromo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH 2 ) 2 PPABr), 3-chloro-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine ((NH 2 ) 2 PPACl), 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPAI), 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPABr) and 3-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (PPACl).

8. The method of claim 1 , wherein the fluorophore has an emission wavelength of from about 400 nm to about 800 nm and is selected from the group consisting of coumarins, resorufins, xanthenes, naphthyamines, cyanines, rhodamines, acridines and bodipy analogs.

9. The method of claim 1 , wherein the fluorophore selected from the group consisting of cyanines, BODIPY analogs, 5-FAM, 6-FAM, TET™, JOE™ HEX™, VIC™, NED™, TAMRA™, ROX™, Bothell Blue™ and Yakima Yellow™ (YY).

10. The method of claim 1 , wherein the quencher has an absorption maximum of from about 400 nm to about 800 nm and is selected from the group consisting of bis azo dyes, dabcyl, TAMRA and carboxytetramethyl rhodamine.

11. The method of claim 1 , wherein the incubating step is carried out in the presence of a polymerase with 5′-nuclease activity and the detecting step comprises continuously monitoring the amplification by monitoring fluorescence produced upon conjugate hybridization to an amplified target and cleavage by 5′-nuclease activity.

12. A kit for detecting nucleic acid amplification, said kit comprising:

(a) a plurality of oligonucleotide primers complementary to regions of a target sequence;

(b) a polymerizing enzyme;

(c) a plurality of nucleotide substrates; and

(d) an oligonucleotide probe comprising a 5′ end and a 3′ end and two or more labels, wherein the oligonucleotide probe is an oligonucleotide conjugate, wherein one of the labels is a fluorophore and one of the labels is a quencher, wherein the oligonucleotide conjugate comprises an oligonucleotide or a modified oligonucleotide, wherein the oligonucleotide or modified oligonucleotide sequence has an overlap of from 1 to 7 bases with at least one of said primer sequences and the oligonucleotide or modified oligonucleotide has a sequence complementary to a portion of the target sequence being amplified.

Assignments (5)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 11, 2022
From: ELITECHGROUP, INC.
To: ELITECHGROUP MDX LLC
Reel/Frame 058615/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: ELITECHGROUP B.V.
To: ELITECHGROUP, INC.
Reel/Frame 048078/0553 →
CHANGE OF NAME Recorded Mar 10, 2017
From: ELITECH HOLDING BV
To: ELITECHGROUP B.V.
Reel/Frame 041974/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2010
From: MAHONEY, WALT; VERMEULEN, NICOLAAS M.J.; AFONINA, IRINA
To: EPOCH BIOSCIENCES, INC.
Reel/Frame 024095/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2010
From: EPOCH BIOSCIENCES, INC.
To: ELITECH HOLDING B.V.
Reel/Frame 024095/0305 →
Continuity (4)
Continuation 11958895 · Dec 18, 2007
Continuation 11202627 · Aug 11, 2005
Provisional Application 60601206 · Aug 13, 2004
Related Publication 20110027780A1 · Feb 3, 2011